<DOC>
	<DOCNO>NCT00077935</DOCNO>
	<brief_summary>The purpose study evaluate safety Civamide Cream 0.075 % Treatment Subjects Osteoarthritis ( OA ) Knee ( ) .</brief_summary>
	<brief_title>Civamide OA Knee ( )</brief_title>
	<detailed_description>This 52-week open label study wherein subject require apply study drug knee ( ) three time day . Subjects require return clinic every 13 week . Enrollment Visit ( Day 1 ) At End-of-Study/Final Visit , Day 84 Study No . WL-1001-05-01 ( preferably &lt; 30 day follow visit ) subject invited enroll long-term open label Study WL-1001-05-04 . Subjects sign write informed consent prior enrol long-term open label study . If enrol final visit &lt; 30 day final visit Study No . WL-1001-05-01 , final visit physical examination laboratory examination serve baseline study . If enrol &gt; 30 day final visit , new physical examination laboratory examination complete upon enrollment study . The subject complete OA Pain Score Subject Global Evaluation ( SGE ) Target Knee , knee designate Target Knee Study No . WL-1001-05-01 . A 13-week supply study drug subject diary next 13 week dispense subject . Instructions apply study drug review subject . Subjects also instruct complete diary daily ( Adverse Events Log Other Medications Log ) return complete diary study drug tube clinic visit . Treatment Period ( Days 1- 365 ) Subjects apply study drug Target Knee three time day 52 week . If subject 's knee affect osteoarthritis pain , may treat study drug well . The study drug tube weigh prior dispense subject . Each tube also weigh subject return . At clinic visit , study staff review diary subject completeness legibility . Subjects complete OA Pain Score Subject Global Evaluation clinic visit Day 1 Weeks 13 , 26 , 39 , 52 . Concurrent medication , adverse event , study drug compliance review record study staff throughout Treatment Period clinic visit Weeks 13 , 26 , 39 , 52 ( End-of-Study/Final Visit ) . At week 52 visit ( End-of-Study/Final Visit ) , physical examination laboratory examination perform . On Day 365 ( End-of-Study/Final Visit ) subject discharge procedure complete .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Inclusion Criteria Subject voluntarily agree participate study sign IRBapproved inform consent . Subject participate ( withdrawn secondary adverse event ) Phase 3 Osteoarthritis Study WL10010501 complete EndofStudy/Final Visit preferably &lt; 30 day prior Day 1 study ( WL10010504 ) . Subject 40 76 year age . Subject generally good health . Subject expect compliant study procedure . Female subject childbearing potential must negative urine pregnancy test Day 1 . Female subject childbearing potential agree use approve form contraception must contraceptive method dosage schedule entire study . Exclusion Criteria Presence tendonitis , bursitis , partial complete joint replacement knee ( ) . Presence active skin disease , erythema , infection , wound , irritation near treatment area knee ( ) . Subject anticipated need surgical invasive procedure ( e.g. , synovial fluid aspiration , arthroscopy , tidal joint irrigation , injectable medication ) perform knee course study . Subject history and/or diagnosis rheumatoid arthritis , fibromyalgia , connective tissue disease , psoriatic arthritis , erosive inflammatory OA , diffuse idiopathic skeletal hyperostosis , severe neurologic vascular disease . Subject active ( redness , swell , fever , etc . ) gout pseudogout within 6 month prior screen . Subject Type I Type II diabetes peripheral neuropathy . Subject trauma surgery knee ( ) within 1 year prior Enrollment Period . Subject underlying clinical condition , include previous malignancy Investigator 's judgment , unstable . Subject know allergy hypersensitivity capsicum , civamide , capsaicincontaining product constituent cream formulation . Subject history substance abuse within past 12 month . Use certain medication within give restriction period prior randomization study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>February 2004</verification_date>
</DOC>